Because MTX-531 targets two of the three critical signaling nodes targeted in these trials, we investigated the therapeutic impact of combining it with the MEK inhibitor trametinib to treat KRAS-mutant and BRAF-mutant CRC PDX models. This evidence concerns the gene MAP2K7 and colorectal carcinoma.